<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="41948">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01951924</url>
  </required_header>
  <id_info>
    <org_study_id>I10E-0901</org_study_id>
    <nct_id>NCT01951924</nct_id>
  </id_info>
  <brief_title>LIME Study (LFB IVIG MMN Efficacy Study)</brief_title>
  <acronym>LIME</acronym>
  <official_title>A European, Randomised, Double-blind, Active Comparator Controlled, Cross-over, Efficacy and Safety Study of a New 10% Ready To-use Liquid Human Intravenous Immunoglobulin (I10E) Versus Kiovig® in Patients With Multifocal Motor Neuropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratoire français de Fractionnement et de Biotechnologies</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>TFS Trial Form Support</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Laboratoire français de Fractionnement et de Biotechnologies</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <authority>France: Committee for the Protection of Personnes</authority>
    <authority>Italy: Agenzia Italiana del Farmaco</authority>
    <authority>Spain: Agencia Española de Medicamentos y Productos Sanitarios</authority>
    <authority>Spain: Comité Ético de Investigación Clínica</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <authority>United Kingdom: Research Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the efficacy and safety of I10E (LFB 10% ready-to-use
      liquid human intravenous immunoglobulin) compared to Kiovig® for the maintenance treatment
      of MMN in a randomized, double-blind, active comparator-controlled, cross-over trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multifocal motor neuropathy (MMN) is a chronic acquired, probably autoimmune, demyelinating,
      motor neuropathy. It is a rare disease, variable in its clinical features. The disease
      course is usually steadily progressive.

      Intravenous immunoglobulin (IVIG) is the standard and the first line treatment for MMN. The
      Cochrane review of four randomized placebo-controlled studies showed a significant clinical
      improvement in muscle strength from IVIG in 78% of patients with MMN versus 4% with placebo
      but a non-significant improvement in disability (39% versus 11%) (van Schaik IN, 2005).
      However, IVIG treatment does not prevent a mild gradual decline in muscle strength which is
      probably due to ongoing axonal degeneration. In addition to its efficacy, IVIG is also a
      safe treatment with a positive benefit-risk ratio in MMN.

      Muscle strength measured with the Modified Medical Research Council (MMRC 10) sum score as
      described in the study of Cats (Cats EA, 2008) including 20 movements i.e. 10 muscle groups
      of the upper and lower limbs on each side was selected as the primary endpoint. Other
      parameters of muscle strength such as measurement of grip strength by dynamometer - and
      functional disability will also be evaluated to reinforce the robustness of the study and
      substantiate the efficacy of I10E in MMN patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <primary_completion_date type="Anticipated">November 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change between I10E and Kiovig® in the original MMRC 10 sum score described by Cats 2008</measure>
    <time_frame>between 3 and 6 months and between 9 and 12 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change between I10E and Kiovig® in: MMRC 10 new sum score (10 slightly different muscles on both sides)</measure>
    <time_frame>at 6 months and 1 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AEs observed and reported TAAEs (temporally associated AE) beginning at infusion or within 72H after infusion</measure>
    <time_frame>from 49 to 56 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change between I10E and Kiovig® in : Rash built MMRC sum score (CATs 2008)</measure>
    <time_frame>at 6 months and 1 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change between I10E and Kiovig® in : INCAT: upper and lower limbs</measure>
    <time_frame>at 6 months and 1 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change between I10E and Kiovig®: Grip strengh</measure>
    <time_frame>at 6 months and 1 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change between I10E and Kiovig® in: MMRC 14 sum score</measure>
    <time_frame>at 6 months and 1 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Motor Neuron Disease</condition>
  <arm_group>
    <arm_group_label>Group A: I10E then Kiovig</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 g/kg for 1-3 days every 4 weeks ±7 days Up to 2 g/kg for 2-5 days every 4 weeks ±7 days to 8 weeks ±7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B : Kiovig then I10E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 g/kg for 1-3 days every 4 weeks ±7 days Up to 2 g/kg for 2-5 days every 4 weeks ±7 days to 8 weeks ±7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Biological : I10E (Human normal Immunoglobulin for intravenous administration 100mg/mL)</intervention_name>
    <arm_group_label>Group A: I10E then Kiovig</arm_group_label>
    <arm_group_label>Group B : Kiovig then I10E</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Biological: Kiovig® (Human normal Immunoglobulin for intravenous administration 100mg/mL)</intervention_name>
    <arm_group_label>Group A: I10E then Kiovig</arm_group_label>
    <arm_group_label>Group B : Kiovig then I10E</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female patient aged 18 to 80 years.

          2. Written informed consent obtained prior to any study-related procedures.

          3. Diagnosis of definite or probable MMN according to the EFNS/PNS Guideline 2010, First
             revision made by neuromuscular disease specialists with specific electrodiagnostic
             expertise.

          4. Patients treated with a stable maintenance dose (without any change in doses &gt; or &lt;
             15% ) of any brand of IVIG (Kiovig excluded) at 1 g/kg body weight every 4-week
             intervals up to 2 g/kg body weight every 4-week to 8-week intervals according to the
             EFNS/PNS Guideline 2010, First revision for at least 3 months prior to enrolment.

          5. Covered by national health care insurance system if required by local regulations.

        Exclusion Criteria:

          1. Upper motor neuron, bulbar, cranial nerve or significant sensory deficit.

          2. CSF protein &gt;100 mg/dL (if available and done as part of a previous evaluation).

          3. Any disease that may cause neuropathy or may interfere with outcome assessments, such
             as diabetes, vasculitis, or systemic lupus erythematosus.

          4. BMI &gt;= 40 kg/m2.

          5. Known hypersensitivity to the active substance or to any of the excipients of I10E
             (glycine and polysorbate 80) or Kiovig(glycine).

          6. History of Kiovig use.

          7. History of IgA deficiency, except if the absence of anti-IgA antibodies is
             documented.

          8. Patient infected with hepatitis B virus (HBV) and/or hepatitis C virus (HCV), or
             human immunodeficiency virus (HIV).

          9. Protein-losing enteropathy characterised by serum protein levels &lt;60 g/l and serum
             albumin levels &lt;30 g/l or nephrotic syndrome characterised by proteinuria &gt;=3.5 g/24
             hours, serum protein levels &lt;60 g/l and serum albumin levels &lt;30 g/l.

         10. History of cardiac insufficiency (New York Heart Association (NYHA) III/IV) or
             uncontrolled severe hypertension.

         11. History of thrombotic episodes (including deep vein thrombosis, pulmonary embolism,
             myocardial infarction, cerebrovascular accident).

         12. Glomerular filtration rate &lt;80 ml/min/1.73m2 measured according to the Modified Diet
             in Renal Disease (MDRD) calculation.

         13. Serum levels of AST, ALT and/or ALP &gt;2 times upper limit of normal range.

         14. Patient treated with immunomodulator/immunosuppressor (e.g. cyclophosphamide,
             cyclosporine or interferon), except use at the same dose of: methotrexate,
             mycophenolate mofetil, or azathioprine for at least 6 months before the inclusion
             visit.

         15. Treatment with an anti-CD20 antibody within the 12 previous months.

         16. Administration of another investigational product within the last month prior to
             inclusion.

         17. Exposure to blood products or derivatives other than commercial IgG, within 3 months
             prior to inclusion.

         18. Positive results of pregnancy blood test or breast-feeding woman or woman of
             childbearing potential without effective contraception for the duration of the study.

         19. Any serious medical condition that would interfere with the clinical assessment of
             I10E or prevent the patient from complying with the protocol requirements.

         20. Anticipated poor compliance of patient with study procedures during the 12 month
             duration of the study.

         21. Drug or alcohol abuse.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Marc LEGER, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital de la Pitié Salpêtrière - Paris 75013</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alain SADOUN, MD</last_name>
    <phone>+33 (0) 1 69 82 56 12</phone>
    <email>sadoun@lfb.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mazen ELZAABI, MD</last_name>
    <email>elzaabi@lfb.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU de Bordeaux -Hôpital Haut-Lévêque</name>
      <address>
        <city>Bordeaux</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Gwendal Le Masson, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Créteil - Groupe Hospitalier Henri Mondor</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Alain Creange, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU Lille - Hôpital Roger Salengro</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Arnaud LACOUR, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Lyon - Hôpital Pierre Wertheimer</name>
      <address>
        <city>Lyon</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Christophe VIAL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Marseille - Hôpital de La Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jean Pouget, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nice - Hôpital l'Archet</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Claude DESNUELLE, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Saint Etienne - Hôpital Nord</name>
      <address>
        <city>Saint Etienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jean Christophe Antoine, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRCCS Istituto Clinico Humanitas</name>
      <address>
        <city>Milan</city>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Eduardo NOBILE-ORAZIO, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria San Giovanni Battista</name>
      <address>
        <city>Turin</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Dario COCITO, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ricardo ROJAS-GARCIA, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politècnic La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Teresa Sevilla, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2WB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Yusuf RAJABALLY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Preston Hospital</name>
      <address>
        <city>Preston</city>
        <zip>PR2 9HT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>John Nixon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southampton General Hospital</name>
      <address>
        <city>Southampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Haider Katifi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 24, 2013</lastchanged_date>
  <firstreceived_date>September 20, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multifocal Motor Neuropathy</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Motor Neuron Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
